Galmed pivots from biopharma into GI MedTech via a Colospan acquisition. Boston Scientific drops $138 million on a new Indiana distribution hub. CardioComm and Predictiv AI link up on automated ECG interpretation. And J&J plus Medtronic co-invest $85 million in a brain-fluid device startup. Four stories, four different vectors of where the sector is moving this week. Issue #29 starts here.
Top Stories
Lead Story
Story 01
Galmed Pharmaceuticals (Nasdaq: GLMD), a biopharma company known for its liver disease and GI oncology pipeline, has agreed to acquire Colospan Ltd., a commercial-stage GI medical device company. The deal, expected to close in Q2 2026 pending standard conditions, will fold Colospan into Galmed as a wholly owned subsidiary, giving the acquiring company a new device-based platform alongside its existing therapeutic assets.
The centerpiece of the acquisition is Colospan's CG-100 intraluminal bypass device, which received FDA Breakthrough Device Designation and is currently enrolled in a U.S. key IDE study designed to support a future PMA submission. The device addresses a specific problem in colorectal surgery: protecting surgical anastomoses from leak complications, which occur in up to 21% of procedures and carry high morbidity, extended hospital stays, and significant cost. The CG-100 is designed to reduce reliance on diverting stomas, a common but quality-of-life-compromising workaround surgeons use when worried about a leak. CE Mark clearance gives Colospan a commercial runway in Europe and Israel, with Germany, Austria, and Switzerland as priority launch markets. Galmed is committing $6 million to an initial European launch in H2 2026.
Why It Matters
Galmed is not a natural acquirer of medical devices. The company built its reputation on small-molecule therapeutics in liver disease. The Colospan acquisition is a deliberate strategic pivot, not a bolt-on. That matters for how to read it. A biopharma company paying $4.5 million in cash and stock for a device with FDA Breakthrough Designation, CE Mark in hand, and a key trial underway is making a bet that the device revenue timeline is more predictable than the therapeutic one. The colorectal surgery market Galmed is targeting exceeds $6 billion. The CG-100 addresses a problem with known clinical burden, a clear regulatory path, and a commercial foothold in Europe. If the key trial reads clean, this is not a niche product. It is a platform.
M&A
GI Devices
FDA
Story 02
Boston Scientific (NYSE: BSX) has announced plans to build a 500,000-square-foot global distribution and light manufacturing facility in Plainfield, Indiana, with an investment of $138 million and a commitment to create up to 300 high-wage jobs. Governor Mike Braun's office confirmed the announcement. The facility, to be located at Plainfield Innovation Park, is designed to support and enhance Boston Scientific's U.S.-based distribution and logistics operations, incorporating state-of-the-art technology and light manufacturing capabilities, with full regulatory compliance processes built in.
Groundbreaking is scheduled for later this year. The announcement follows confirmed $88 million R&D investment in Ireland and a Minnesota facility expansion in 2026, marking the third major infrastructure commitment Boston Scientific has disclosed this year.
Why It Matters
When large MedTech companies announce domestic infrastructure buildouts, pay attention. Boston Scientific is not building a factory because it ran out of space. It is building because the regulatory, supply chain, and tariff environment has shifted enough that U.S.-based distribution and light manufacturing infrastructure now pencils out in ways it did not three years ago. A 500,000-square-foot facility handling global distribution is a signal about where the company sees risk in its supply chain and where it wants control. The 300 jobs and Indiana's life sciences credentials are the local story. The infrastructure investment is the global one.
Infrastructure
Supply Chain
Boston Scientific
Story 03
CardioComm Solutions (TSXV: EKG), a provider of consumer heart monitoring and medical ECG software, has entered a strategic collaboration and joint development agreement with Predictiv AI Inc. of North York, Ontario. The agreement establishes a framework for pursuing projects in advanced remote patient monitoring, automated ECG and biosignal interpretation, clinical workflow automation, and predictive analytics, with a specific focus on regulated software applications.
Predictiv AI brings capabilities in telemetry aggregation, data intelligence, and predictive analytics, while CardioComm contributes its proprietary ECG management technology, ISO 13485 quality management system, and FDA and Health Canada regulatory clearances. For regulated deliverables, CardioComm retains final decision-making authority over quality, cybersecurity, and validation matters. The CEO of CardioComm, Etienne Grima, also serves as a director of Predictiv AI, a relationship he disclosed and recused himself from in the board approval process.
Why It Matters
Remote patient monitoring has been a growth area since COVID-19, but the regulatory and quality barrier to entry for advanced diagnostic software has always been the ISO 13485 and cybersecurity piece. CardioComm already has those. Predictiv AI has the data analytics layer. The collaboration is a classic complement-fit deal: one partner has regulatory infrastructure, the other has technical capability, and neither has to build it from scratch. The CEO cross-directorship is a disclosure point, not a disqualifier. Joint ventures between a public company and an associate company happen. What matters is whether the projects that come out of the framework have commercial validity.
AI
Remote Monitoring
Diagnostics
Story 04
CereVasc has closed an $85 million Series C financing round co-led by Piper Sandler Merchant Banking and backed by Bain Capital Life Sciences, J&J's corporate venture capital arm, Medtronic, and Perceptive Xontogeny Venture Funds. The round will fund an ongoing U.S. key trial of the company's eShunt system, a minimally invasive treatment for normal pressure hydrocephalus that uses femoral venous access rather than traditional skull drilling to drain excess cerebrospinal fluid from the brain.
The eShunt is designed to address the complications associated with the standard ventriculoperitoneal shunt procedure. Claims data shows 25% of VP shunt patients experience complications or readmission within 30 days of surgery. CereVasc's one-hour procedure with overnight hospital observation could support outpatient use in the future. The key trial compares eShunt to the surgical VP shunt procedure, with a primary efficacy endpoint assessing gait improvement at six months and a primary safety endpoint tracking adverse events. The company expects primary completion by December 2026. It is working toward a future PMA filing and U.S. commercialization.
Why It Matters
Normal pressure hydrocephalus is an underdiagnosed condition that affects a significant patient population, primarily elderly, with symptoms that include gait disturbance, mild cognitive decline, and urinary incontinence. The existing standard of care is a surgical shunt procedure with a known complication profile. CereVasc is not replacing the indication, it is improving the delivery mechanism. The co-investment by J&J and Medtronic is notable: Medtronic sells hydrocephalus devices and exited Codman Neurosurgery to Integra in 2017, so this is a re-entry via a different mechanism. J&J is making a calculated bet on a different approach to a space it once owned.
Funding
Neurology
FDA
The Signal
The four stories this week add up to a pattern: the MedTech sector is getting more specific in where it bets, and more deliberate in how it builds. Galmed is not diversifying casually, it is buying into a specific device category with a defined clinical problem, a regulatory designation, and a market size attached. Boston Scientific is building infrastructure because the operational environment demands it, not because it has idle capital to deploy. CardioComm and Predictiv AI are pairing complementary assets rather than trying to build end-to-end capability internally. And J&J plus Medtronic backing a neuro device startup is a signal about where two of the sector's largest players see the next wave of procedural innovation. None of these are incremental moves. They are targeted bets on defined clinical and operational problems, funded by companies that have enough visibility into their own supply chains and markets to know what they are solving for.
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG | Intuitive Surgical | $472.80 | ▲ 1.0% |
| SYK | Stryker | $305.40 | ▲ 0.3% |
| BDX | Becton Dickinson | $238.90 | ▲ 0.5% |
| JNJ | Johnson & Johnson | $227.50 | ▲ 0.4% |
| ABT | Abbott Laboratories | $113.80 | ▲ 0.5% |
| EW | Edwards Lifesciences | $83.20 | ▲ 0.2% |
| BSX ★ | Boston Scientific | $80.10 | ▲ 1.3% |
| MDT | Medtronic | $79.70 | ▲ 0.6% |
| GEHC | GE HealthCare | $65.70 | ▲ 0.9% |
| STE | Stevanato Group | $65.30 | ▼ 0.2% |
★ Biggest Mover: Boston Scientific (BSX) gained 1.3% following the announcement of a $138M Indiana distribution and light manufacturing facility, a signal of supply chain investment and infrastructure build. Sorted by stock price, highest to lowest. Prices reflect approximate close, week of June 8, 2026. For illustrative purposes only.
⏳ That's your 5-minute briefing. Below: extras if you want to go deeper.
Fun Fact
💡 Fun Fact: CereVasc eShunt by the Numbers
CereVasc's eShunt uses femoral venous access to treat hydrocephalus without drilling a skull. An FDA key trial could read out by year-end.
Trivia
MedTech Trivia
What specific clinical mechanism makes CereVasc's eShunt different from a standard ventriculoperitoneal shunt for treating normal pressure hydrocephalus, and what does the key trial use as its primary efficacy endpoint?
If you're building, hiring, or investing in MedTech, reply and tell me what you're seeing. I read every response.
